Related Experiment Video
Updated: Apr 3, 2026
03:47
Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
Published on: September 27, 2024
1.7K
New and Emerging Treatments for Rosacea
Lauren M Gold1, Zoe Diana Draelos2
1Henry Ford Hospital, 6530 Farmington Road, West Bloomfield, Detroit, MI, 48322, USA. laurgold@umich.edu.
American Journal of Clinical Dermatology
|September 24, 2015
Summary
New treatments for rosacea, a common inflammatory skin condition, are emerging. This review covers recent FDA-approved and investigational options like ivermectin and azelaic acid foam, discussing their therapeutic roles and side effects.
Area of Science:
- Dermatology
- Inflammatory Disorders
- Pharmacology
Background:
- Rosacea is a prevalent chronic inflammatory skin condition affecting millions.
- Its complex pathophysiology remains incompletely understood.
- Recent advancements have introduced novel therapeutic agents.
Purpose of the Study:
- To review emerging treatment options for rosacea.
- To discuss the clinical utility of new rosacea medications.
- To provide insights into patient selection and adverse effects.
Main Methods:
- Literature review of recent clinical trials and FDA approvals.
- Analysis of pharmacological data for new rosacea treatments.
- Synthesis of information on ivermectin, brimonidine, azelaic acid foam, and oxymetazoline.
Main Results:
- Several new agents, including ivermectin, brimonidine, azelaic acid foam, and oxymetazoline, show promise.
- These treatments target various aspects of rosacea pathophysiology.
- Understanding patient selection and potential adverse effects is crucial for effective use.
Conclusions:
- Novel therapeutic options offer new hope for managing rosacea.
- Personalized treatment strategies considering patient profiles and drug-specific profiles are essential.
- Ongoing research and clinical trials continue to expand the rosacea treatment landscape.
Related Concept Videos
01:27Acne Infection
52
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
52
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
562
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
562
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
608
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608